CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent glioblastoma multiforme (“GBM”). Presented at the 29th Annual Meeting of the Society for Neuro-Oncology, the data show balanced patient demographics and safety profiles between the study arms, with Berubicin showing comparable adverse event rates and promising potential to improve overall survival (“OS”), the trial’s primary endpoint. With enrollment completed at 252 patients, CNS expects to report primary analysis data in early 2025. Berubicin holds FDA Fast Track and Orphan Drug Designations, underscoring its significance in advancing GBM treatment options.
To view the full press release, visit https://ibn.fm/HLAYs
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as…
Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug…
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, reported continued progress on its proprietary AI…
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a…
Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to…
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid…